

CHBG NEWSLETTER

The Cochrane Hepato-Biliary Group (THE CHBG)

Volume 18, Issue 1

March 2014

IN THIS ISSUE

PUBLICATIONS IN THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS (CDSR) IN THE COCHRANE LIBRARY (THE CLIB). ISSUE 10 OF 2013 THROUGH ISSUE 2 OF 2014

NEW REGISTERED TITLES

THE CHBG PUBLICATION STATUS IN 2013

PAST EVENTS

CHBG EXHIBITION STAND DURING THE 64TH ANNUAL AASLD MEETING, WASHINGTON, DC, USA. NOVEMBER 1 TO NOVEMBER 5, 2013

FUTURE EVENTS

CHBG EXHIBITION STAND DURING THE 49TH ANNUAL EASL MEETING, LONDON, UK. APRIL 10 TO APRIL 12, 2014

THE 34TH BI-ANNUAL CHBG MEETING. LONDON, UK. APRIL 11, 2014.

DIAGNOSIS AND PROGNOSIS: CLINICAL RESEARCH WORKSHOP. GARGNANO, ITALY. OCTOBER 8 TO 11, 2014

VISITORS

REQUIREMENTS FOR CO-PUBLICATION OF A COCHRANE PROTOCOL OR REVIEW IN A PAPER JOURNAL

METHODOLOGICAL STANDARDS FOR THE CONDUCT AND REPORTING OF COCHRANE INTERVENTION REVIEWS (MECIR)

STANDARDS FOR THE REPORTING OF PLAIN LANGUAGE SUMMARIES IN NEW COCHRANE INTERVENTION REVIEWS (PLEACS)

TRAINING

NEWS

THE 34TH BI-ANNUAL CHBG MEETING PROGRAMME. APRIL 11, 2014. LONDON

The numbering is a continuation from Vol. 17, Issue 2, 2013.

PUBLICATIONS IN THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS (CDSR) IN THE COCHRANE LIBRARY (THE CLIB). ISSUE 10 OF 2013 THROUGH ISSUE 2 OF 2014

NEW REVIEWS

163. Microwave coagulation for liver metastases. Bala MM, Riemsma RP, Wolff R, Kleijnen J.
164. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Eslami L, Merat S, Malekzadeh R, Nasserri-Moghaddam S, Aramin H.
165. Laparoscopic surgical box model training for surgical trainees with no prior laparoscopic experience. Nagendran M, Toon CD, Davidson BR, Gurusamy KS.
166. Fewer-than-four ports versus four ports for laparoscopic cholecystectomy. Gurusamy KS, Vaughan J, Rossi M, Davidson BR.
167. Formal education of patients about to undergo laparoscopic cholecystectomy. Gurusamy KS, Vaughan J, Davidson BR.
168. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Glud C.
169. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Glud C, Glud LL.

UPDATED REVIEWS

63. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR
64. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Gurusamy KS, Tsochatzis E,



- Toon CD, Davidson BR, Burroughs AK.
65. Surgical versus endoscopic treatment of bile duct stones. Dasari BVM, Tan CJ, Gurusamy KS, Martin DJ, Kirk G, McKie L, Diamond T, Taylor MA.
66. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Weis S, Franke A, Mössner J, Jakobsen JC, Schoppmeyer K.
67. Dopamine agents for hepatic encephalopathy. Junker AE, Als-Nielsen B, Gluud C, Gluud LL.

NEW AND UPDATED PROTOCOLS

270. Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease. Lin S, Xiao K, Liu Y, Su P, Chen P, Zhang Y, Bai Y.
271. Organic nitrates for prevention of oesophageal varices bleeding and re-bleeding. Ma H, Suo T, Zhang W, Fu D, Liu T, Zhao N.
272. Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinoma. Shao W, Song J.
273. Fibrin-based haemostatic agents for reducing blood loss in adult liver resection. Amer AO, Wilson CH, White SA, Manas DM.
274. Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinoma. Zhang Q, Bai XL, Chen W, Ma T, Liu H, Zhang Y, Hu XJ, Liang TB.
275. Antiviral agents for hepatitis B virus-related cirrhosis. Atallah E, Eslami L, Isazadefar K.

NEW REGISTERED TITLES

457. Surgical portosystemic shunts versus devascularisation procedures for variceal bleeding as a result of hepatosplenic schistosomiasis. Ede CJ, Brand M.
458. Fish oil-based lipid emulsions versus standard lipid emulsions for parenteral nutrition-associated liver disease in children. Alberti G, Castet A, Villarroel del Pino LA, Cifuentes LI, Rivera-Cornejo M, Gana JC.
459. Fish oil-based lipid emulsions versus standard lipid emulsions for prevention of parenteral nutrition-associated liver disease in children. Gana JC, Castet A, Villarroel del Pino LA, Cifuentes LI, Torres-Robles R, Alberti G.
460. Carvedilol versus non-selective beta-blockers for portal hypertension. Hobolth L, Gluud LL.
461. Enhanced recovery versus standard care for

- recovery following open liver resection. Shemmer P, Kenya Y, Mohammed A-S, Zhou D.
462. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Israelsen M, Krag A, Rohde J, Gluud LL.
463. Pentoxifylline for non-alcoholic hepatitis. Chen Y, Li R, Zhang S, Qing Q, Zhi F.

THE CHBG PUBLICATION STATUS IN 2013

In the whole 2013, the CHBG published 18 new protocols, 10 new reviews, and 18 updated reviews in the Cochrane Database of Systematic Reviews database which is one of the databases within The Cochrane Library.

The new registered titles were 15. In the case when authors could not continue with their protocols or reviews, other people were allowed to overtake the unfinished or unstarted work.

PAST EVENTS

CHBG EXHIBITION STAND DURING THE 64TH ANNUAL AASLD MEETING, WASHINGTON, DC, USA. NOVEMBER 1 TO NOVEMBER 5, 2012

We thank all who have visited the stand and attended the CHBG meeting.

FUTURE EVENTS

CHBG EXHIBITION STAND DURING THE 49TH ANNUAL EASL MEETING, LONDON, UK. APRIL 10 TO APRIL 12, 2014

The CHBG stand is number 105. We are happy to see you there and reply to your questions.

The EASL Congress and Exhibition venue is: ExCel London, One Western Gateway, Royal Victoria Dock London, E16 1XL / UK.

www.excel-london.co.uk

THE 34TH BI-ANNUAL CHBG MEETING. LONDON, UK. APRIL 11, 2014.

It will be run **from 9:15 am to 11:45 am** on April 11, in **room 1 & 2, Library, Ground Floor, Royal Free Hospital, at Pond Street London, NW3 2QG.**

Please note that this is not the EASL venue, and it may take you approximately an hour to reach the Royal Free Hospital if you start from the Congress Centre.



To find the way to the Royal Free Hospital, you may use the following link:

http://www.royalfree.org.uk/default.aspx?top_nav_id=1&tab_id=109

The 34th biannual CHBG meeting programme is sent out with this Newsletter. See also The CHBG website.

It will help us a lot in terms of catering and further planning, if we receive mails from people if they will attend the CHBG meeting or not.

Please send an email to dimitrinka.nikolova@ctu.dk. On the subject line, please write "CHBG meeting – London".

DIAGNOSIS AND PROGNOSIS: CLINICAL RESEARCH WORKSHOP. GARGNANO, ITALY. OCTOBER 8 TO 11, 2014

The workshop is planned to be held at Palazzo Feltrinelli, Gargnano, Lago di Garda, Italy. The aim of this workshop is to provide the tools for understanding the methodology underlying the diagnostic test accuracy (DTA) and prognostic studies.

At the end of the workshop, participants will be able to perform critical appraisals of diagnostic accuracy studies and make extraction and interpretation of data to build DTA meta-analyses. The architecture for the design of a diagnostic accuracy study will also be provided.

If you are interested in attending the workshop, please send an e-mail to Ms Sara Comparetti, Centro Interuniversitario 'Thomas C. Chalmers' Università degli Studi di Milano at chalmers@unimi.it, requesting her to be sent a registration form, a workshop programme, or get your questions answered.

For the workshop program and for updates on it, you may also check the CHBG website: hbg.cochrane.org.

The CHBG Editorial Team Office will be most happy also to answer your questions.

VISITORS

Chavdar Pavlov from Russia, and *Giovanni Casazza* and *Agostino Colli* from Italy visited the CHBG Editorial Team Office from 20 and 21 to 26 of October 2013. Chavdar and Giovanni continued their work on the 'Transient elastography for diagnosis of hepatic fibrosis in people with alcoholic liver disease' review. *Giovanni* and *Agostino* (both CHBG editors and authors of reviews) worked on peer reviewing tasks as well as on the 'Capsule endoscopy for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosis' review.

Goran Bjelakovic from Serbia visited the CHBG Editorial Team Office from 27 of January to 22 of February, 2014. Goran worked on the update of published systematic reviews as well as on new reviews on vitamin D.

Chavdar Pavlov from Russia visited the CHBG Editorial Team Office from 1 and 9 of March 2014. Chavdar continued his work on the 'Transient elastography for diagnosis of hepatic fibrosis in people with alcoholic liver disease' review.

REQUIREMENTS FOR CO-PUBLICATION OF A COCHRANE PROTOCOL OR REVIEW IN A PAPER JOURNAL

The CHBG has always encouraged authors to co-publish Cochrane protocols and reviews. However, there are central requirements that need to be observed. *PLEASE READ CAREFULLY!*

The requirements are provided through the link: <http://www.cochrane.org/editorial-and-publishing-policy-resource/requirements-co-publication> but we find it highly important to provide the text (with



Volume 17, Issue 2

omissions of the lists and templates given in the Appendices) also here as Cochrane authors are not always aware of this.

1. For all instances of co-publication, the authors should approach the Managing Editor of the CHBG using the 'Permission to co-publish form'.
2. If the authors propose publishing an abridged version in a journal:
 - a. before publication in the Cochrane Database of Systematic Reviews (CDSR) (prior publication) – CHBG will refer the case to the Central Editorial Unit (CEU) for permission.
 - b. at the same time as publication in the CDSR (simultaneous publication) – the CHBG will refer the case to the CEU for permission or inform us if there is an existing co-publication agreement with the journal.
 - c. after publication in the CDSR (post-publication) but either the journal has not yet signed a Cochrane co-publication agreement or if the journal appears on the list of high-profile journals – the CHBG will refer the case to the CEU for permission. The CEU will consult with the CHBG, the authors, and the journal, as necessary. The CEU will ask Wiley to ensure that the journal signs a Cochrane co-publication agreement and that permission is granted to the author. The CEU will inform the CHBG of the decision, and we will communicate the decision to the author.
 - d. after publication in the CDSR (post-publication) AND the journal has already signed a Cochrane co-publication agreement – the CHBG can grant permission to the author and does not need to refer to the CEU. The CHBG will ensure that the CEU is aware of each permission granted by sending a copy of the completed 'Permission to co-publish' form to the CEU.
3. All co-publishing journals will be asked to sign a Cochrane co-publication agreement with Wiley.

This can be a one-off agreement or an agreement to co-publish over a period of time (i.e., it does not need to be signed by the journal for each abridged review).

All journals that have already signed the agreement to co-publish over a period of time are listed below. If the journal has not yet signed an agreement the CEU will instruct Wiley to ensure that an agreement is signed (in advance of submission to the journal as far as possible).

4. When submitting an abridged version of a Cochrane Review to a journal (or enquiring about submission in the case of prior or simultaneous publication), the author must make a complete statement to the journal editor to say that the article is based on a Cochrane Review (published or in progress).

5. The journal version must faithfully reflect the data and interpretations of the Cochrane version. Where journal editing and peer review have resulted in differences in the data or interpretation, these should be discussed with the CHBG, and, where appropriate, incorporated into a revised version of the Cochrane Review at the next available opportunity, and with appropriate acknowledgement to the journal's peer reviewers/editors.

5. The title of the journal version should indicate that it is a secondary publication (complete republication, abridged republication, complete translation, or abridged translation) of the Cochrane Review, preferably by including 'Cochrane Review' or 'Cochrane Systematic Review' in the title.

7. The support of the CHBG in publishing the Cochrane Review should be acknowledged in an appropriate place in the journal version (e.g., in the Acknowledgements section).

8. The Cochrane Review must be cited in the reference list of the journal version.

- a. A footnote should be placed on the title page of the journal version to inform readers and documenting agencies that the paper has been published previously, either in whole or in part, citing the primary publication (CDSR); for example:
"This article is based on a Cochrane Review published in the *Cochrane Database of Systematic Reviews* (CDSR) YYYY, Issue X, DOI: 10.1002/14651858.CD00xxxx



(see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the *CDSR* should be consulted for the most recent version of the review.”

- b. The Cochrane Review published in the *CDSR* should reference the journal version in the section ‘Other published versions of this review’ as soon as possible after publication of the journal version or when in press.

The workflow will help CHBG and authors to navigate the processes for discussing and arranging co-publication. The CHBG will communicate the co-publishing decision to the authors or seek additional information using the available template.

METHODOLOGICAL STANDARDS FOR THE CONDUCT AND REPORTING OF COCHRANE INTERVENTION REVIEWS (MECIR)

All Cochrane authors shall use the standards of conduct and reporting when developing a protocol or

a review. These two standards are available from the Central Editorial Unit website: <http://www.editorial-unit.cochrane.org/mecir>

The Iberoamerican Cochrane Centre has translated the conduct and reporting standards into Spanish, available from

http://www.cochrane.es/files/MECIR_esp_web.pdf

STANDARDS FOR THE REPORTING OF PLAIN LANGUAGE SUMMARIES IN NEW COCHRANE INTERVENTION REVIEWS (PLEACS)

See <http://www.editorial-unit.cochrane.org/mecir>

TRAINING

For current training possibilities, see

<http://www.cochrane.org/training>

NEWS

For latest news, visit <http://www.cochrane.org/>

The Cochrane Hepato-Biliary Group (The CHBG) Newsletter is published in electronic and paper format. It is issued twice a year and is also distributed for free world-wide to all people on The CHBG members’ list who have contributed, are contributing, or have shown interest in the work of The CHBG. The purpose with The CHBG Newsletter is to inform its readers about activities of The CHBG.

Editorial CHBG staff at The CHBG Editorial Office

Christian Gluud, Co-ordinating & Criticism Editor, E-mail: cgluud@ctu.dk;
Dimitrinka Nikolova, Managing Editor, E-mail: dimitrinka.nikolova@ctu.dk;
Sarah Louise Klingenberg, Trials Search Co-ordinator, E-mail: slk@ctu.dk;
Thomas Nexø, IT-help, E-mail: TMN@ctu.rh


Postal address

The Cochrane Hepato-Biliary Group | Copenhagen Trial Unit,
Centre for Clinical Intervention Research
Department 7812, Rigshospitalet, Blegdamsvej 9, Copenhagen Ø, DK-2100
Tel. +45 3545 7169 or +45 3545 7175 | Fax +45 3545 7101
Web site: hbg.cochrane.org

Visiting address

Department 7812, Tagensvej 22, 2nd floor, Copenhagen N, DK-2200

Newsletter Editors: Dimitrinka Nikolova and Christian Gluud.



THE COCHRANE HEPATO-BILIARY GROUP

MEETING PROGRAMME

THE CHBG

The 34th biannual Cochrane Hepato-Biliary Group meeting will take place on **Friday, April 11, 2014, from 9:10am to 11:45am. Location: Room 1 & 2, Library, Ground Floor, Royal Free Hospital, Pond Street London, NW3 2QG.**

Attendance is free.

Chairs: Christian Gluud, DK and Brian Davidson, UK.

9:10am to 9:20am	Welcome and program introduction.	<u>C Gluud (DK), Davidson, UK.</u>
9:20am to 9:35am	The effect of interferon monotherapy retreatment on clinical and surrogate outcomes.	<u>RL Koretz (USA), M Pleguezuelo (ES), V Arvaniti (GR), P Barrera Baena (ES), R Ciria (ES), KS Gurusamy (UK), BR Davidson (UK), AK Burroughs (UK).</u>
9:35am to 9:50am	Sustained virological response is a good prognostic marker of treatment response but a poor surrogate of treatment outcome for chronic hepatitis C infection.	<u>KS Gurusamy (UK), K Thorlund (CA), E. Wilson (UK), RL Koretz (USA), BR Davidson (UK), AK Burroughs (UK), C Gluud, (DK).</u>
9:50am to 10:05am	Nitazoxanide for chronic hepatitis C. A Cochrane Hepato-Biliary Group systematic review.	<u>K Nikolova (DK), C Gluud (DK), B Grevstad (DK), JC Jakobsen (DK)</u>
10:05am to 10:20am	Albumin and other plasma expanders for paracentesis treatment of ascites in cirrhotic patients. A Cochrane Hepato-Biliary Group systematic review.	<u>RG Simonetti (ITA), G Perricone (ITA), G Bjelakovic (RS), C Gluud (DK).</u>
10:20am to 10:35am	Pharmacological interventions for primary prevention of gallbladder stones in adults. A Cochrane Hepato-Biliary Group systematic review.	<u>CS Stokes (GER), LL Gluud LL (DK), M Casper (GER), F Lammert (GER).</u>
10:35am to 10:50am	Endoscopic ultrasound versus magnetic resonance cholangiopancreatography for common bile duct stones. A Cochrane Hepato-Biliary Group systematic review.	<u>V Giljaca (CRO), KS Gurusamy (UK), D. Higgle (UK), G Poropat (CRO), D. Štimac (CRO), BR Davidson (UK).</u>
10:50am to 11:10am	Discussions.	All.
11:10am to 11:25am	How to get a Cochrane review underway - for prospective review authors.	<u>D. Nikolova (DK), C Gluud (DK)</u>
11:25am to 11:45am	Any other business.	The CHBG editors.

Improving healthcare decision-making globally, through systematic reviews of the effects of healthcare interventions, published in *The Cochrane Library*.

The CHBG website <hbg.cochrane.org>